For research purposes only. Not for human use. BPC-157 is not approved by any regulatory agency and is banned in professional sport. Nothing here is medical advice or an administration protocol.
What BPC-157 Is
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular weight of 1,419 Da. It is a partial sequence of a protein discovered in and isolated from human gastric juice by Predrag Sikirić's group, and it has been studied by that group and others for over three decades, mostly in rat models of injury.
Three features distinguish it from other research peptides. It is stable in gastric juice, which is unusual for a peptide and is why oral administration has been used in many animal studies. It is active without a carrier or formulation. And its reported effects span an unusually wide range of tissues: gastrointestinal mucosa, tendon, ligament, muscle, bone, blood vessels and nervous tissue. That breadth is also the reason for scepticism, because a single peptide that heals everything in one laboratory's models invites the question of whether the models, rather than the peptide, are doing the work. This guide summarises the evidence with that question in view.
Mechanisms Proposed in the Literature
Angiogenesis through VEGFR2. The best-characterised molecular mechanism comes from Hsieh and colleagues, a group separate from the Sikirić laboratory. BPC-157 increased vessel density in the chick chorioallantoic membrane assay and in endothelial tube-formation assays, accelerated blood-flow recovery in rat hind-limb ischaemia, and up-regulated VEGFR2 expression in both ischaemic muscle and cultured endothelial cells. Mechanistically it promoted VEGFR2 internalisation together with activation of the VEGFR2–Akt–eNOS pathway (Hsieh et al., 2017).
Fibroblast migration through FAK–paxillin. Chang and colleagues showed that BPC-157 accelerated outgrowth of tendon fibroblasts from rat Achilles explants, improved cell survival under oxidative stress and increased in vitro migration. Proliferation was not directly affected; instead, phosphorylation of FAK and paxillin increased dose-dependently while total protein was unchanged, pointing to an adhesion-and-migration mechanism rather than a mitogenic one (Chang et al., 2011).
Nitric-oxide system modulation. The Sikirić group has repeatedly reported that BPC-157 interacts with the nitric-oxide system in both directions: it counteracts the effects of the NOS inhibitor L-NAME and of excess L-arginine, affects thrombosis and bleeding depending on the model, and stimulates early-response genes such as egr-1. A 2014 review in Current Pharmaceutical Design lays out this "NO-system relation" hypothesis (Sikirić et al., 2014); a 2025 update frames the same idea as maintaining the protective actions of nitric oxide while targeting its cytotoxic ones (Pharmaceuticals, 2025).
Dopamine and gastrointestinal sphincters. In a one-week rat study, dopamine antagonists and L-NAME lowered pressure in the lower oesophageal and pyloric sphincters and raised oxidative-stress markers in plasma, sphincter and brain tissue; BPC-157 counteracted these effects (Inflammopharmacology, 2017). This is the basis for the group's claims of a dopamine–NO–BPC-157 relationship.
Musculoskeletal Research
The tendon work is the most replicated part of the BPC-157 literature and the part with contributions from outside the Sikirić group.
In transected rat Achilles tendon, daily intraperitoneal BPC-157 improved the Achilles functional index and the biomechanical and histological quality of the repair; the same paper reported that BPC-157 stimulated tendon fibroblast outgrowth and counteracted the inhibitory effect of the aldehyde 4-hydroxynonenal in vitro (Staresinic et al., 2003). In a tendon-to-bone model (Achilles detachment from the calcaneus), BPC-157 promoted healing where controls failed to reattach (Krivic et al., 2006).
In muscle, BPC-157 given intraperitoneally or as a topical cream accelerated healing of gastrocnemius crush injury in rats, judged macroscopically, microscopically, functionally and by serum enzyme markers (Novinscak et al., 2008), and improved muscle healing impaired by systemic corticosteroids (Pevec et al., 2010).
The most useful recent independent data come from a 2026 study by Biçer and colleagues comparing BPC-157, TB-500 and their combination in rat Achilles transection and repair over four weeks with biomechanical, histopathological and immunohistochemical readouts. Both peptides improved healing measures versus control; the combination showed no additive effect, which the authors attributed, with appropriate caution, to convergence on shared downstream pathways (Biçer et al., 2026). This is the only controlled head-to-head study of the two peptides that are most often sold together, and it does not support the common assumption that stacking them is synergistic.
Two 2025 reviews take stock of this literature for orthopaedic readers. A systematic review in HSS Journal concludes that BPC-157 shows promise in preclinical musculoskeletal models while noting the absence of FDA approval, its prohibition in professional sport, and the risks from unregulated manufacturing and contamination (HSS J, 2025). A narrative review in Current Reviews in Musculoskeletal Medicine reaches the same conclusion, calling the compound investigational and emphasising the need for well-designed human trials (Curr Rev Musculoskelet Med, 2025).
Gastrointestinal Research
BPC-157 began as an anti-ulcer peptide, and the Sikirić group's gastrointestinal work is extensive: gastric and duodenal lesions, oesophagitis, sphincter dysfunction, colitis, fistulas and anastomosis healing. The 2006 Inflammopharmacology paper describes cytoprotective effects in the fully distended rat stomach after alcohol instillation and recovery of oesophageal and pyloric sphincter pressure after long-standing esophagitis, and states that BPC-157 was safe in clinical trials for inflammatory bowel disease under the Pliva codes PL-10, PLD-116 and PL 14736 (Sikirić et al., 2006). Those IBD trials are the only human trials of BPC-157 that appear in the peer-reviewed record, and their results were never published as primary papers; the safety statement is a summary from the developers, not a peer-reviewed trial report. A 2024 review updates the gastrointestinal work with a focus on counteracting vascular occlusion and the "cytoprotection" framework (Inflammopharmacology, 2024), and a 2022 review covers the vascular-occlusion and ischaemia-reperfusion models in detail (World J Gastroenterol, 2022).
Wound Healing and Nervous System
A 2021 review in Frontiers in Pharmacology summarises skin-wound work (incisional and excisional wounds, deep burns, diabetic ulcers, alkali burns) and notes that BPC-157 rapidly increases the expression of multiple genes in rat excision wounds; it also repeats the group's claim that no toxicity was seen and that an LD1 was not reached in toxicology (Seiwerth et al., 2021). The nervous-system literature, reviewed in Neural Regeneration Research in 2022, covers stroke after bilateral carotid clamping, L-NAME- and haloperidol-induced catalepsy, and spinal cord compression in rats (Vukojević et al., 2022).
Human Data: What Actually Exists
The human evidence for BPC-157 is thin enough to list in full. There are the Pliva IBD trials referenced in the developers' own reviews, whose primary results were never published. There is one retrospective chart review of intra-articular BPC-157 for knee pain from a private clinic in Florida, published in Alternative Therapies in Health and Medicine, with no control group, no imaging follow-up and no blinded outcome assessment (Lee and Padgett, 2021). And there is no completed phase 2 trial for any indication.
A 2026 review in Pharmaceutics states that after three decades of consistent preclinical activity, BPC-157 has no approved formulation, no validated dosing regimen, no characterised pharmacokinetics and no completed phase 2 trial. The authors argue the barrier to translation is not lack of biological activity but the absence of basic pharmaceutical science (Pharmaceutics, 2026). Every claim about BPC-157 in humans, positive or negative, is therefore extrapolation from animal data.
BPC-157 vs TB-500
The two peptides are compared and combined more than any other pair on the research market. They differ in origin (gastric protein fragment versus a synthetic fragment of thymosin β4), in size (15 residues versus 43), in the best-characterised mechanism (VEGFR2/FAK-paxillin versus actin sequestration), and in the depth of the tendon literature (BPC-157's is larger). The one direct comparison in a controlled model found both effective and the combination not additive. A fuller treatment is in BPC-157 vs KPV vs LL-37 and the TB-500 sourcing guide.
Platform Market Data: BPC-157 Listings
BPC-157 is the most widely listed peptide in the Peptides.SO database (10,922 priced listings across 119 suppliers, prices checked 24–25 September 2026).
| Product row | Listings | Suppliers | Median list price | Interquartile range | Median at sale |
|---|---|---|---|---|---|
| BPC-157 (all sizes) | 191 | 97 | $65.00 | $46.37 – $119.50 | $60.99 |
| BPC-157 5 mg | 31 | 27 | $49.99 | — | — |
| BPC-157 10 mg | 36 | 32 | $64.98 | — | — |
| BPC-157 / TB-500 blend | 89 | 65 | $107.00 | $65.00 – $160.00 | $99.99 |
| BPC-157 / TB-500 / KPV / GHK-Cu blend | 19 | 16 | $55.00 | $39.99 – $142.45 | $52.00 |
| BPC-157 capsules (1,000 mcg) | 7 | 6 | $117.99 | — | — |
The main-row range runs from $13.99 to $619.60; the top end is multi-vial kits stored under the same product row. The BPC-157/TB-500 blend carries a median premium of about $42 over BPC-157 alone, which buyers may want to weigh against the 2026 rat study finding no additive benefit. The oral capsule products are priced at roughly twice the injectable-vial median for a small fraction of the peptide mass, on the strength of the gastric-stability data; whether orally delivered BPC-157 reaches systemic tissues in any species has not been established by pharmacokinetic study.
Live prices, stock and supplier count are on the BPC-157 product page and the BPC-157/TB-500 blend page. The cost calculator converts list prices to cost per milligram across vial sizes; the supplier checklist sets out what a certificate of analysis should contain. Because BPC-157 is a linear 15-mer with no disulfides or modifications, mass spectrometry confirming 1,419 Da and HPLC purity are straightforward tests that any competent supplier can provide.
Handling Notes for Laboratory Use
BPC-157 is supplied as a lyophilised powder and is water-soluble. Its stability in acidic conditions is unusual for a peptide, but it remains subject to the ordinary rules: store lyophilised vials frozen and desiccated, reconstitute in sterile water or bacteriostatic water, refrigerate solutions, aliquot to avoid freeze-thaw cycles, and protect from light. The peptide calculator converts vial mass and diluent volume to concentration. These are handling notes for laboratory material only; the animal studies cited above report their own regimens and none of them describe use in humans.
Frequently Asked Questions
Is BPC-157 approved anywhere?
No. It has no approved formulation in any jurisdiction and is banned in professional sport. It is sold as a research chemical.
What is the strongest evidence for its mechanism?
VEGFR2 up-regulation and internalisation with Akt–eNOS activation (Hsieh 2017) and FAK–paxillin-dependent fibroblast migration (Chang 2011), both from groups outside the original Sikirić laboratory.
Has it been tested in humans?
Only in the Pliva IBD trials referenced by the developers, whose results were never published as primary papers, and one uncontrolled retrospective chart review of knee injections. No completed phase 2 trial exists.
Does combining BPC-157 with TB-500 work better than either alone?
The only controlled comparison, a 2026 rat Achilles study, found both improved healing and the combination was not additive.
Why is oral BPC-157 sold?
Because the peptide survives gastric juice and many rat studies used oral administration. Systemic bioavailability after oral dosing has not been characterised in any species.
How much does research-grade BPC-157 cost?
The platform median is $65 across 97 suppliers; 5 mg vials have a median of $49.99 and 10 mg vials $64.98. Prices vary more than three-fold between suppliers for the same vial size.
References
1. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. PMID 27847966
2. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PMID 21030672
3. Sikirić P, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014. PMID 23755725
4. Sikirić P, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Preserving, and Restoring Its Beneficial Effects. Pharmaceuticals (Basel). 2025. PMID 41155565
5. Belosic Halle Z, et al. Class side effects: decreased pressure in the lower oesophageal and the pyloric sphincters after the administration of dopamine antagonists, neuroleptics, anti-emetics, L-NAME, pentadecapeptide BPC 157 and L-arginine. Inflammopharmacology. 2017. PMID 28516373
6. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003. PMID 14554208
7. Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006. PMID 16583442
8. Novinscak T, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008. PMID 18668315
9. Pevec D, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010. PMID 20190676
10. Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026. PMID 42542926
11. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID 40756949
12. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. PMID 40789979
13. Sikirić P, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Inflammopharmacology. 2006. PMID 17186181
14. Sikirić P, et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology. 2024. PMID 38980576
15. Sikirić P, et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World J Gastroenterol. 2022. PMID 35125818
16. Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021. PMID 34267654
17. Vukojević J, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022. PMID 34380875
18. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. PMID 34324435
19. Mateescu DM, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Considerations. Pharmaceutics. 2026. PMID 42198317
Research Disclaimer
BPC-157 is sold for laboratory research only. It has no approved use, no validated human pharmacokinetics and no completed efficacy trial in any indication. This article summarises published animal and in vitro research and does not recommend or describe administration to people or animals.